ABBV vs RTX: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
AbbVie Inc. · Healthcare
$216.63
+3.8% upside to fair value
Grade C
High Quality
VS
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
ABBV has more upside to fair value
(+3.8%).
RTX trades at a lower forward P/E
(34.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
RTX |
| Current Price |
$216.63 |
$185.60 |
| Fair Value Estimate |
$224.76 |
$138.81 |
| Upside to Fair Value |
+3.8%
|
-25.2%
|
| Market Cap |
$382.7B |
$249.9B |
| Forward P/E |
106.2x
|
34.3x
|
| EV / EBITDA |
26.4x
|
18.3x
|
| Price / Sales |
6.1x
|
2.8x
|
| Price / FCF |
18.3x
|
29.9x
|
| Revenue Growth YoY |
+12.4%
|
+8.7%
|
| Gross Margin |
70.7%
|
20.2%
|
| Operating Margin |
27.6%
|
10.9%
|
| Return on Equity |
68.0%
|
11.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.45%
|
3.34%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in pharmaceuticals with a strong focus on immunology, aesthetics, neuroscience, and oncology. The company benefits from a durable competitive moat driven by its immunology franchises, global commercial scale, and R&D capabilities, although it faces challenges from the post-Humira patent cliff and intense competition in biologics and small m…
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
| Metric |
ABBV |
RTX |
| Zone Low |
$168.57 |
$104.11 |
| Zone High |
$191.05 |
$117.99 |
| In Buy Zone? |
No
|
No
|